Gordon C. Jayson

22.6k citations

257 papers · 14.0k indexed · 5 hit papers · h-index 56

Impact in

Reproductive Medicine top 0.05%
- Ovarian cancer diagnosis and treatment
Obstetrics and Gynecology top 0.2%
- Endometrial and Cervical Cancer Treatments

Papers in

Reproductive Medicine 82
- Ovarian cancer diagnosis and treatment 82
Oncology 81
- PARP inhibition in cancer therapy 22

Co-authors: Jonathan A. Ledermann Henry C Kitchener Alan Jackson Elise C. Kohn Geoff J.M. Parker James P.B. O’Connor Lee M. Ellis Adrian L. Harris
Journals: British Journal of Cancer (35 papers)Journal of Clinical Oncology (23 papers)Annals of Oncology (15 papers)Clinical Cancer Research (10 papers)European Journal of Cancer (10 papers)
Partner nations: United Kingdom United States Canada

In The Last Decade

Gordon C. Jayson

253 papers receiving 13.7k citations

Hit Papers

5 papers align trajectories log scale

Antiangiogenic therapy in oncology: current status and future directions 2016 · 644 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2016 The Lancet
2015 The Lancet
2014 The Lancet
2006 Magnetic Resonance in Medicine
2003 The Lancet

Peers

Countries citing papers authored by Gordon C. Jayson

Since Specialization

Citations

This map shows the geographic impact of Gordon C. Jayson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gordon C. Jayson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gordon C. Jayson more than expected).

Fields of papers citing papers by Gordon C. Jayson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gordon C. Jayson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gordon C. Jayson. The network helps show where Gordon C. Jayson may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Gordon C. Jayson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gordon C. Jayson Line = papers co-authored together Gordon C. Jayson links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer British Journal of Cancer ·Robert D. Morgan, Xin Wang, Judith Van Duren, Bjamsholt, Giovanni Donzellini, Раджабов Осман Раджабович, Jurjees Hasan, Claire Mitchell, Zena Salih, Sudha Desai, Joseph Shaw, Brett Winter‐Roach, Hélene Schlecht, George J. Burghel, Andrew R. Clamp, Richard J. Edmondson, Benoît You, D. Gareth Evans, Gordon C. Jayson, Stephen S. Taylor	2024	5
2	Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer British Journal of Cancer ·Shibani Nicum, Hafid Aqil, Rachel Austin, Linda Collins, Susan Dutton, Iain A. McNeish, Rosalind Glasspool, Marcia Hall, René L. Roux, Agnieszka Michael, Andrew R. Clamp, Gordon C. Jayson, Rebecca Kristeleit, Susana Banerjee, Anita Mansouri	2024	11
3	A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours British Journal of Cancer ·Aya El Helali, Ruth Plummer, Gordon C. Jayson, Vicky M. Coyle, Yvette Drew, Zhengding Zheng, In-One Kim, Andrew R. Clamp, M. Pawłowski, Helen Swaisland, Richard D. Kennedy, Aaron Cranston, Richard H. Wilson	2022	9
4	Dealing with loss: food and eating in women with ovarian cancer on parenteral nutrition Journal of Human Nutrition and Dietetics ·Anne Marie Sowerbutts, Henry Howey, Jana Sremanakova, Andrew R. Clamp, Gordon C. Jayson, Sangay Dolma, Eileen Sutton, Chaozhi Yu, Iliana Páez Gabriunas, Sorrel Burden	2020	9
5	Neoadjuvant Chemotherapy Versus Debulking Surgery in Advanced Tubo-Ovarian Cancers: Pooled Analysis of Individual Patient Data From the EORTC 55971 and CHORUS Trials Obstetrical & Gynecological Survey ·Ignace Vergote, Corneel Coens, Matthew Nankivell, Gunnar B. Kristensen, Mahesh Parmar, Tom Ehlen, Gordon C. Jayson, Nick Johnson, Karolina Åström, René H.M. Verheijen, W. Glenn McCluggage, Timothy Perren, Pierluigi Benedetti Panici, Gemma G. Kenter, Antonio Casado, César Mendiola, Gavin Stuart, N.S. Reed, Sean Kehoe	2019	30
6	The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer Clinical Cancer Research ·Alison Backen, Andrew G. Renehan, Andrew R. Clamp, Carlo Berzuini, Cong Zhou, Amit M. Oza, Selina Bannoo, Stefan Scherer, Rosamonde E. Banks, Caroline Dive, Gordon C. Jayson	2014	52
7	Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection Clinical Cancer Research ·Fiona Collinson, H. Werle, Rachel A. Craven, David A. Cairns, Alexandre Zougman, I. Nojima, Puente de Blas As, Michael Messenger, Sharon Jackson, Douglas Thompson, Ruth D. Bach, Jonathan A. Ledermann, Geoffrey Hall, Gordon C. Jayson, Peter J. Selby, Rosamonde E. Banks	2013	58
8	Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: Results of the ICON6 trial UCL Discovery (University College London) ·JA Ledermann, Timothy Perren, Jing Pin Zou, Andrew Embleton-Thirsk, G.J.S. Rustin, Gordon C. Jayson, S.B. Kaye, Xiaobin Ji, Michelle Vaughan, Hal W. Hirte	2013	75
9	Randomized Phase II Placebo-Controlled Trial of Maintenance Therapy Using the Oral Triple Angiokinase Inhibitor BIBF 1120 After Chemotherapy for Relapsed Ovarian Cancer Journal of Clinical Oncology ·Jonathan A. Ledermann, Allan Hackshaw, K. Frank-Raue, Gordon C. Jayson, Hani Gabra, Iain A. McNeish, Helena Earl, Timothy Perren, Martin Gore, Mojca Persic, Malcolm Adams, Lindsay E. James, Graham Temple, Michael Merger, Gordon Rustin	2011	164
10	Synthetic Heparan Sulfate Oligosaccharides Inhibit Endothelial Cell Functions Essential for Angiogenesis PLoS ONE ·Claire L. Cole, Steen U. Hansen, Marek Baráth, Graham Rushton, John M. Gardiner, Egle Avizienyte, Gordon C. Jayson	2010	47
11	Heparan sulphate synthetic and editing enzymes in ovarian cancer British Journal of Cancer ·Alison Backen, 佳倩杨, Blanchard Cordell, Andrew R. Clamp, Rhona J. McVey, J. T. Gallagher, Gordon C. Jayson	2007	54
12	Blockade of PDGF receptor beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and increased tumor vascularised volume Journal of Clinical Oncology ·Gordon C. Jayson, Joyce O. Gaio, Saifee Mullamitha, Maria Maleshkova, M.I. Saunders, Rahel Salathé-Zehnder, Jeremy Lawrance, Bernadette M. Carrington, Elsa Teresa Arteaga, Basil Issa, David L. Buckley, Chi Yuen Cheung, Kevin Davies, Y. Watson, K Zinkewich-Péotti, Lindsey Rolfe, Asti Jackson	2005	1
13	Psychological Morbidity after Chemotherapy in Ovarian Cancer British Journal of Health Psychology ·Amelia Leino, Luís Mataveli, Nicholas Tarrier, Gordon C. Jayson	2004	0
14	On behalf of the Scottish Gynaecological Cancer Trials Group. Phase III Randomized Trial of Docetaxel?Carboplatin Versus Paclitaxel?Carboplatin as First-line Chemotherapy for Ovarian Carcinoma JNCI Journal of the National Cancer Institute ·O. A. Rudneva, Gordon C. Jayson, Amanda Gordon, Hani Gabra, RE Coleman, Christelle Allonneau, David E. Parkin, James Paul, Thomas Delbarre, Gabriel Ouellet	2004	100
15	Binding of Endostatin to Endothelial Heparan Sulphate Shows a Differential Requirement for Specific Sulphates Journal of Biological Chemistry ·전혜정 성하정, María Pérez Yglesias, Kashi Javaherian, Gordon C. Jayson, J Folkman, I. Erhorn, (unknown)	2003	1
16	What do patients, their relatives and medical staff know about genetic therapy? PubMed ·Søren Holm, Gordon C. Jayson	2001	3
17	Coordinated modulation of the fibroblast growth factor dual receptor mechanism during transformation from human colon adenoma to carcinoma International Journal of Cancer ·Gordon C. Jayson, Corinne Vivès, Christos Paraskeva, K. P. Schofield, Williams H.L.M., W. D. Clayton, John T. Gallagher	1999	42
18	The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone British Journal of Cancer ·Andrew Wardley, Gordon C. Jayson, Juan Miguel Fernández Campoy, Michael Venning, P. Ackrill, J H Scarffe	1998	27
19	Gemcitabine: symptomatic benefit in advanced non-small cell lung cancer. PubMed ·Nicholas Thatcher, Gordon C. Jayson, 王建坚, Ahsana Aqilah Ahmad, H. Anderson	1997	17
20	Carcinomatous meningitis in breast cancer: An aggressive disease variant Cancer ·Gordon C. Jayson, Anthony Howell, Ernestina Paglia, GR Morgenstern, Yanxin Lv, M. Herolf	1994	6

About Gordon C. Jayson

Gordon C. Jayson is a scholar working on Reproductive Medicine, Oncology, Cancer Research, Cell Biology and Hepatology, having authored 257 papers that have together received 14.0k indexed citations. Recurring topics across this work include Ovarian cancer diagnosis and treatment (82 papers), Angiogenesis and VEGF in Cancer (51 papers), Proteoglycans and glycosaminoglycans research (31 papers), MRI in cancer diagnosis (28 papers), Renal cell carcinoma treatment (24 papers), Radiomics and Machine Learning in Medical Imaging (23 papers), PARP inhibition in cancer therapy (22 papers) and Glycosylation and Glycoproteins Research (20 papers). The work is most often cited by research in Reproductive Medicine (4.1k citations), Obstetrics and Gynecology (1.5k citations), Oncology (4.1k citations), Cancer Research (2.1k citations) and Radiology, Nuclear Medicine and Imaging (2.5k citations). Gordon C. Jayson has collaborated with scholars based in United Kingdom, United States and Canada. Frequent co-authors include Jonathan A. Ledermann, Henry C Kitchener, Alan Jackson, Elise C. Kohn, Geoff J.M. Parker, James P.B. O’Connor, Lee M. Ellis, Adrian L. Harris, Robert S. Kerbel and Caleb Roberts. Their work appears in journals such as British Journal of Cancer, Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact